Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
The Pharma Data
MARCH 22, 2023
1 Sandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023. 1 Sandoz intends to launch the Hyrimoz citrate-free HCF in the US on July 1, 2023. “As Sandoz has more than two decades of experience researching, developing and bringing biosimilars to markets across the globe. Head of North America.
Let's personalize your content